Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

GSK plc ( NYSE: GSK) and Syndivia on Monday announced an agreement granting GSK exclusive worldwide rights to develop and ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

GSK advanced after saying it had bought the worldwide rights from French biotech firm Syndivia to develop and sell a ...

GSK shares lifted on Monday after the pharmaceutical giant signed a £268m deal with French biotech Syndivia for a potential treatment for prostate cancer.

The market thrives on precision radiotherapy with growth driven by advanced robotics, non-invasive imaging, and adaptive ...

Gerhardt Attard, M.D., Ph.D., from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP versus placebo and AAP in mCSPC with HRR gene ...

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).